Comparative analysis of the efficacy of Mobotinib (Mobosetinib) and Suvotinib

Mobocertinib (Mobocertinib) and Suvotinib (Savolitinib) are both targeted therapeutic drugs targeting specific gene mutations, but there are obvious differences between them in indications, mechanisms of action and efficacy. Mobotinib mainly targets EGFR exon 20 insertion mutations (EGFR Exon20ins), while suvotinib is mainly used to treat patients with MET gene abnormalities (such as METexon14 skipping mutation or METamplification) non-small cell lung cancer. Both drugs bring new treatment hope to patients who are positive for specific molecular markers, but they are applicable to different populations and cannot replace each other.

In terms of efficacy, mobotinib has shown good response rates and disease control rates in patients with EGFRexon20 insertion mutations. According to clinical studies, mobotinib has the potential to improve the efficacy of EGFR in previously treated patients. Among patients with Exon20ins mutations, the objective response rate (ORR) reaches about 28%-35% and the median progression-free survival (PFS) is about 7 months. Compared with traditional EGFR-TKI which has poor effect on Exon20ins mutations, mobotinib significantly improves the therapeutic response and is therefore considered an important option for this niche patient group.

Suvotinib has shown excellent efficacy in the treatment of MET non-small cell lung cancer patients. Research data shows that in patients with METexon 14 skipping mutations, suvotinib has an objective response rate of 43%-50% and a median progression-free survival of about 6.8-9.6 months. Especially for those patients who have not received systemic treatment, the efficacy is more prominent. Since MET gene abnormalities are also a relatively unique molecular subtype in non-small cell lung cancer, suvotinib provides a highly targeted and well-tolerated treatment option.

Generally speaking, mobotinib and suvotinib each target different molecular mutations and have shown good efficacy in their respective indication fields. Patients need to undergo accurate genetic testing before treatment to confirm the specific type of genetic abnormality, and then choose the most appropriate drug under the guidance of a doctor. Reasonable selection of targeted drugs can not only improve the therapeutic effect, but also reduce unnecessary side effects and improve the overall quality of life.

References：https://en.wikipedia.org/wiki/Mobocertinib